Venture Capital News | Private Equity News
Summary
AUSTIN, Texas, September 21, 2022-- MicroTransponder, Inc. positions for continued strategic growth, having finalized its oversubscribed $73 million Series E funding round and named Prashant Rawat chief operating officer (COO). As we embark on the next stage of our companys progress, I am certain he will guide us diligently as COO in identifying and demonstrating the vast potential of Paired VNS Therapy in stroke rehabilitation as well as for other applications. Most recently, he was the COO at Mainstay Medical, where he led research and development, clinical and regulatory efforts from inception to market approval, and scaled operations for commercial launches in Europe, Australia and the United States. Throughout my career, I have been inspired by innovative medical devices that change healthcare delivery while making a difference in peoples lives, and that is the assignment that guides me as I take on the role of MicroTransponders COO. MicroTransponders FDA-approved Vivistim\xae Paired VNS System is a first-of-its-kind, clinically proven medical technology that generates two to three times more improvement in upper limb function than rehabilitation alone for stroke survivors after six weeks of in-clinic therapy.